Familial Partial Lipodystrophy (FPLD): Recent Insights

References

• Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10:375. doi:10.2147/DMSO.S130810
   PubMedGoogle Scholar
• Köbberling J, Willms B, Kattermann R, Creutzfeldt W. Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipatrophic diabetes. Humangenetik. 1975;29(2):111–120. doi:10.1007/bf00430347
   PubMedGoogle Scholar
• Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission: a new syndrome. QJM. 1974;43(1):33–48.
   PubMedGoogle Scholar
• Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest. 2019;42(1):61–73. doi:10.1007/s40618-018-0887-z
   PubMed Web of Science ®Google Scholar
• Melvin A, Stears A, Savage DB. Recent developments in lipodystrophy. Curr Opin Lipidol. 2019;30(4):284–290. doi:10.1097/MOL.0000000000000613
   PubMed Web of Science ®Google Scholar
• Hussain I, Garg A. Lipodystrophy syndromes. Endocrinol Metab Clin. 2016;45(4):783–797. doi:10.1016/j.ecl.2016.06.012
   Google Scholar
• Vigouroux C, Caron-Debarle M, Le Dour C, Magré J, Capeau J. Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity. Int J Biochem Cell Biol. 2011;43(6):862–876. doi:10.1016/j.biocel.2011.03.002
   PubMed Web of Science ®Google Scholar
• Huang-Doran I, Sleigh A, Rochford JJ, O’Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol. 2010;207(3):245–255. doi:10.1677/JOE-10-0272
   PubMed Web of Science ®Google Scholar
• Virtue S, Vidal-Puig A. It’s not how fat you are, it’s what you do with it that counts. PLoS Biol. 2008;6(9):e237. doi:10.1371/journal.pbio.0060237
   PubMed Web of Science ®Google Scholar
• Wong SPY, Huda M, English P, et al. Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. Diabetologia. 2005;48(12):2641–2649. doi:10.1007/s00125-005-0038-x
   PubMedGoogle Scholar
• Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87(5):2395–2398. doi:10.1210/jcem.87.5.8624
   PubMed Web of Science ®Google Scholar
• Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015;64(1):131–145. doi:10.1016/j.metabol.2014.10.016
   PubMed Web of Science ®Google Scholar
• Sarmento ASC, Lima JG, de Souza Timoteo AR, et al. Changes in redox and endoplasmic reticulum homeostasis are related to congenital generalized lipodystrophy type 2. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;158610.
   PubMedGoogle Scholar
• Mathew H, Castracane VD, Mantzoros C. Adipose tissue and reproductive health. Metabolism. 2018;86:18–32. doi:10.1016/j.metabol.2017.11.006
   PubMed Web of Science ®Google Scholar
• Kawwass JF, Summer R, Kallen CB. Direct effects of leptin and adiponectin on peripheral reproductive tissues: a critical review. Mol Hum Reprod. 2015;21(8):617–632. doi:10.1093/molehr/gav025
   PubMed Web of Science ®Google Scholar
• Dib K, Whitehead JP, Humphreys PJ, et al. Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance. J Clin Invest. 1998;101(5):1111–1120. doi:10.1172/JCI119884
   PubMedGoogle Scholar
• Lotta LA, Wittemans LBL, Zuber V, et al. Association of genetic variants related to gluteofemoral vs abdominal fat distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors. JAMA. 2018;320(24):2553–2563. doi:10.1001/jama.2018.19329
   PubMed Web of Science ®Google Scholar
• Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17. doi:10.1038/ng.3714
   PubMed Web of Science ®Google Scholar
• Broekema MF, Savage DB, Monajemi H, Kalkhoven E. Gene-gene and gene-environment interactions in lipodystrophy: lessons learned from natural PPARγ mutants. Biochim Biophys Acta Mol Cell Biol Lipids. 2019.
   PubMedGoogle Scholar
• Campeau PM, Astapova O, Martins R, et al. Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARγ deficiency. J Lipid Res. 2012;53(9):1968–1978. doi:10.1194/jlr.P025437
   PubMedGoogle Scholar
• Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 2002;51(12):3586–3590. doi:10.2337/diabetes.51.12.3586
   PubMedGoogle Scholar
• Strissel KJ, Stancheva Z, Miyoshi H, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007;56(12):2910–2918. doi:10.2337/db07-0767
   PubMed Web of Science ®Google Scholar
• Sears IB, MacGinnitie MA, Kovacs LG, Graves RA. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. Mol Cell Biol. 1996;16(7):3410–3419. doi:10.1128/MCB.16.7.3410
   PubMedGoogle Scholar
• Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998;101(6):1354–1361. doi:10.1172/JCI1235
   PubMed Web of Science ®Google Scholar
• Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 1999;22(2):288–293. doi:10.2337/diacare.22.2.288
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Barnes RI, Garg A. Genetic basis of congenital generalized lipodystrophy. Int J Obes. 2004;28(2):336. doi:10.1038/sj.ijo.0802487
   Google Scholar
• Shackleton S, Lloyd DJ, Jackson SNJ, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet. 2000;24(2):153. doi:10.1038/72807
   PubMed Web of Science ®Google Scholar
• Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313–3325. doi:10.1210/jc.2011-1159
   PubMed Web of Science ®Google Scholar
• Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 1999;84(1):170–174.
   PubMed Web of Science ®Google Scholar
• Patni N, Li X, Adams-Huet B, Vasandani C, Gomez-Diaz RA, Garg A. Regional body fat changes and metabolic complications in children with Dunnigan lipodystrophy-causing LMNA variants. J Clin Endocrinol Metab. 2018;104(4):1099–1108. doi:10.1210/jc.2018-01922
   Google Scholar
• Vantyghem MC, Pigny P, Maurage CA, et al. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab. 2004;89(11):5337–5346. doi:10.1210/jc.2003-031658
   PubMed Web of Science ®Google Scholar
• Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52(15):1250–1260. doi:10.1016/j.jacc.2008.06.044
   PubMed Web of Science ®Google Scholar
• Fountas A, Giotaki Z, Dounousi E, et al. Familial partial lipodystrophy and proteinuric renal disease due to a missense c. 1045C> T LMNA mutation. Endocrinol Diabetes Metab Case Rep. 2017;2017(1). doi:10.1530/EDM-17-0049
   PubMedGoogle Scholar
• Simha V, Agarwal AK, Oral EA, Fryns J-P, Garg A. Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy. J Clin Endocrinol Metab. 2003;88(6):2821–2824. doi:10.1210/jc.2002-021575
   PubMed Web of Science ®Google Scholar
• Spear ED, Hsu E-T, Nie L, Carpenter EP, Hrycyna CA, Michaelis S. ZMPSTE24 missense mutations that cause progeroid diseases decrease prelamin A cleavage activity and/or protein stability. Dis Model Mech. 2018;11(7):dmm033670. doi:10.1242/dmm.033670
   PubMed Web of Science ®Google Scholar
• Cassini TA, Robertson AK, Bican AG, et al. Phenotypic heterogeneity of ZMPSTE24 deficiency. Am J Med Genet A. 2018;176(5):1175–1179. doi:10.1002/ajmg.a.38493
   PubMedGoogle Scholar
• Agarwal AK, Fryns J-P, Auchus RJ, Garg A. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet. 2003;12(16):1995–2001. doi:10.1093/hmg/ddg213
   PubMed Web of Science ®Google Scholar
• Gonzalo S, Kreienkamp R, Askjaer P. Hutchinson-Gilford progeria syndrome: a premature aging disease caused by LMNA gene mutations. Ageing Res Rev. 2017;33:18–29. doi:10.1016/j.arr.2016.06.007
   PubMed Web of Science ®Google Scholar
• Bonne G, Yaou RB, Navarro C, et al. Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation. Eur J Hum Genet. 2011;19(6):647–654. doi:10.1038/ejhg.2010.256
   PubMedGoogle Scholar
• Kwan JM, Satter EK. A 53-year-old woman with multifocal subcutaneous nodules. J Am Acad Dermatol. 2015;72(5):924–926. doi:10.1016/j.jaad.2012.06.032
   PubMedGoogle Scholar
• Agarwal AK, Zhou XJ, Hall RK, et al. Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency. J Investigat Med. 2006;54(4):208–213. doi:10.2310/6650.2006.05068
   PubMed Web of Science ®Google Scholar
• George S, Rochford JJ, Wolfrum C, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004;304(5675):1325–1328. doi:10.1126/science.1096706
   PubMed Web of Science ®Google Scholar
• Klatka M, Rysz I, Kozyra K, Polak A, Kołłątaj W. SHORT syndrome in a two-year-old girl–case report. Ital J Pediatr. 2017;43(1):44. doi:10.1186/s13052-017-0362-z
   PubMedGoogle Scholar
• Thauvin-Robinet C, Auclair M, Duplomb L, et al. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am J Hum Genet. 2013;93(1):141–149. doi:10.1016/j.ajhg.2013.05.019
   PubMed Web of Science ®Google Scholar
• Dyment DA, Smith AC, Alcantara D, et al. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet. 2013;93(1):158–166. doi:10.1016/j.ajhg.2013.06.005
   PubMed Web of Science ®Google Scholar
• Alcantara D, Elmslie F, Tetreault M, et al. SHORT syndrome due to a novel de novo mutation in PRKCE (Protein Kinase Cɛ) impairing TORC2-dependent AKT activation. Hum Mol Genet. 2017;26(19):3713–3721. doi:10.1093/hmg/ddx256
   PubMedGoogle Scholar
• Chen FJ, Yin Y, Chua BT, Li P. CIDE family proteins control lipid homeostasis and the development of metabolic diseases. Traffic. 2020;21(1):94–105.
   PubMedGoogle Scholar
• Rubio‐Cabezas O, Puri V, Murano I, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med. 2009;1(5):280–287. doi:10.1002/emmm.200900037
   PubMed Web of Science ®Google Scholar
• Ajjaji D, Ben M’barek K, Mimmack ML, et al. Dual binding motifs underpin the hierarchical association of perilipins1–3 with lipid droplets. Mol Biol Cell. 2019;30(5):703–716. doi:10.1091/mbc.E18-08-0534
   PubMed Web of Science ®Google Scholar
• Jéru I, Vantyghem M-C, Bismuth E, et al. Diagnostic challenge in PLIN1-Associated familial partial lipodystrophy. J Clin Endocrinol Metab. 2019;104(12):6025–6032. doi:10.1210/jc.2019-00849
   PubMedGoogle Scholar
• Laver TW, Patel KA, Colclough K, et al. PLIN1 haploinsufficiency is not associated with lipodystrophy. J Clin Endocrinol Metab. 2018;103(9):3225–3230. doi:10.1210/jc.2017-02662
   PubMedGoogle Scholar
• Zolotov S, Xing C, Mahamid R, Shalata A, Sheikh‐Ahmad M, Garg A. Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy. Am J Med Genet A. 2017;173(1):190–194. doi:10.1002/ajmg.a.37880
   PubMed Web of Science ®Google Scholar
• Albert JS, Yerges-Armstrong LM, Horenstein RB, et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. N Engl J Med. 2014;370(24):2307–2315. doi:10.1056/NEJMoa1315496
   PubMed Web of Science ®Google Scholar
• Garg A, Sankella S, Xing C, Agarwal AK. Whole-exome sequencing identifies ADRA2A mutation in atypical familial partial lipodystrophy. JCI Insight. 2016;1(9). doi:10.1172/jci.insight.86870
   PubMedGoogle Scholar
• Garg A, Agarwal AK. Caveolin-1: A New Locus for Human Lipodystrophy. Oxford University Press; 2008.
   Google Scholar
• Kim CA, Delépine M, Boutet E, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93(4):1129–1134. doi:10.1210/jc.2007-1328
   PubMed Web of Science ®Google Scholar
• Garg A, Kircher M, Del Campo M, Amato RS, Agarwal AK, University of Washington Center for Mendelian G. Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. Am J Med Genet A. 2015;167(8):1796–1806. doi:10.1002/ajmg.a.37115
   Web of Science ®Google Scholar
• Cao H, Alston L, Ruschman J, Hegele RA. Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids Health Dis. 2008;7(1):3. doi:10.1186/1476-511X-7-3
   PubMedGoogle Scholar
• Yamamoto GL, Baratela WAR, Almeida TF, et al. Mutations in PCYT1A cause spondylometaphyseal dysplasia with cone-rod dystrophy. Am J Hum Genet. 2014;94(1):113–119. doi:10.1016/j.ajhg.2013.11.022
   PubMedGoogle Scholar
• Hoover-Fong J, Sobreira N, Jurgens J, et al. Mutations in PCYT1A, encoding a key regulator of phosphatidylcholine metabolism, cause spondylometaphyseal dysplasia with cone-rod dystrophy. Am J Hum Genet. 2014;94(1):105–112. doi:10.1016/j.ajhg.2013.11.018
   PubMedGoogle Scholar
• Liu Y, Ramot Y, Torrelo A, et al. Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 2012;64(3):895–907. doi:10.1002/art.33368
   PubMed Web of Science ®Google Scholar
• Torrelo A. CANDLE syndrome as a paradigm of proteasome-related autoinflammation. Front Immunol. 2017;8:927. doi:10.3389/fimmu.2017.00927
   PubMed Web of Science ®Google Scholar
• Yu C-E, Oshima J, Fu Y-H, et al. Positional cloning of the Werner’s syndrome gene. Science. 1996;272(5259):258–262. doi:10.1126/science.272.5259.258
   PubMed Web of Science ®Google Scholar
• Oshima J, Sidorova JM, Monnat JRJ. Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev. 2017;33:105–114. doi:10.1016/j.arr.2016.03.002
   PubMed Web of Science ®Google Scholar
• Weedon MN, Ellard S, Prindle MJ, et al. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet. 2013;45(8):947. doi:10.1038/ng.2670
   PubMed Web of Science ®Google Scholar
• Cunniff C, Bassetti JA, Ellis NA. Bloom’s syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. Mol Syndromol. 2017;8(1):4–23. doi:10.1159/000452082
   PubMed Web of Science ®Google Scholar
• Sanz MM, German J, Cunniff C. Bloom’s Syndrome Mar 22 [Updated 2016 Apr 7]. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews® [Internet]. Seattle, WA, USA:University of Washington; 2006:1993–2017.
   Google Scholar
• Köbberling J, Dunnigan MG. Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state. J Med Genet. 1986;23(2):120–127. doi:10.1136/jmg.23.2.120
   PubMedGoogle Scholar
• Herbst KL, Tannock LR, Deeb SS, Purnell JQ, Brunzell JD, Chait A. Köbberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care. 2003;26(6):1819–1824. doi:10.2337/diacare.26.6.1819
   PubMed Web of Science ®Google Scholar
• Stenson PD, Ball EV, Mort M, et al. Human gene mutation database (HGMD®): 2003 update. Hum Mutat. 2003;21(6):577–581. doi:10.1002/humu.10212
   PubMed Web of Science ®Google Scholar
• Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500–4511. doi:10.1210/jc.2016-2466
   PubMed Web of Science ®Google Scholar
• Meral R, Ryan BJ, Malandrino N, et al. “Fat Shadows” from DXA for the qualitative assessment of lipodystrophy: when a picture is worth a thousand numbers. Diabetes Care. 2018;41(10):2255–2258. doi:10.2337/dc18-0978
   PubMed Web of Science ®Google Scholar
• Lewandowski KC, Dąbrowska K, Brzozowska M, Kawalec J, Lewiński A. Metformin paradoxically worsens insulin resistance in SHORT syndrome. Diabetol Metab Syndr. 2019;11(1):81. doi:10.1186/s13098-019-0477-z
   PubMedGoogle Scholar
• Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133(4):263–274. doi:10.7326/0003-4819-133-4-200008150-00009
   PubMed Web of Science ®Google Scholar
• Simha V, Rao S, Garg A. Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety. Diabetes Obes Metab. 2008;10(12):1275–1276. doi:10.1111/j.1463-1326.2008.00978.x
   PubMedGoogle Scholar
• Agostini M, Schoenmakers E, Beig J, et al. A pharmacogenetic approach to the treatment of patients with PPARG mutations. Diabetes. 2018;67(6):1086–1092. doi:10.2337/db17-1236
   PubMed Web of Science ®Google Scholar
• Banning F, Rottenkolber M, Freibothe I, Seissler J, Lechner A. Insulin secretory defect in familial partial lipodystrophy type 2 and successful long‐term treatment with a glucagon‐like peptide 1 receptor agonist. Diabet Med. 2017;34(12):1792–1794. doi:10.1111/dme.13527
   PubMed Web of Science ®Google Scholar
• Valerio CM, de Almeida JS, Moreira RO, et al. Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetol Metab Syndr. 2017;9(1):26. doi:10.1186/s13098-017-0226-0
   PubMedGoogle Scholar
• Oliveira J, Lau E, Carvalho D, Freitas P. Glucagon-like peptide-1 analogues-an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports. J Med Case Rep. 2017;11(1):12. doi:10.1186/s13256-016-1175-1
   PubMedGoogle Scholar
• Ulahannan TJ, D’Emden M. Sustained, successful treatment of diabetes in lipodystrophy by dapagliflozin. 2018.
   Google Scholar
• Hamaguchi T, Hirota Y, Takeuchi T, et al. Treatment of a case of severe insulin resistance as a result of a PIK 3R1 mutation with a sodium–glucose cotransporter 2 inhibitor. J Diabetes Investig. 2018;9(5):1224–1227. doi:10.1111/jdi.12825
   PubMedGoogle Scholar
• Kawana Y, Imai J, Sawada S, Yamada T, Katagiri H. Sodium–glucose cotransporter 2 inhibitor improves complications of lipodystrophy: a case report. Ann Intern Med. 2017;166(6):450–451. doi:10.7326/L16-0372
   PubMedGoogle Scholar
• Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531–542. doi:10.1056/NEJMoa1715944
   PubMed Web of Science ®Google Scholar
• Ciudin A, Baena‐Fustegueras JA, Fort JM, Encabo G, Mesa J, Lecube A. Successful treatment for the Dunnigan‐type familial partial lipodystrophy with Roux‐en‐Y gastric bypass. Clin Endocrinol. 2011;75(3):403. doi:10.1111/j.1365-2265.2011.04057.x
   PubMed Web of Science ®Google Scholar
• Utzschneider KM, Trence DL. Effectiveness of gastric bypass surgery in a patient with familial partial lipodystrophy. Diabetes Care. 2006;29(6):1380–1382. doi:10.2337/dc06-0130
   PubMed Web of Science ®Google Scholar
• Melvin A, Adams C, Flanagan C, et al. Roux-en-Y gastric bypass surgery in the management of familial partial lipodystrophy type 1. J Clin Endocrinol Metab. 2017;102(10):3616–3620. doi:10.1210/jc.2017-01235
   PubMed Web of Science ®Google Scholar
• Dollfus C, Blanche S, Trocme N, Funck‐Brentano I, Bonnet F, Levan P. Correction of facial lipoatrophy using autologous fat transplants in HIV‐infected adolescents. HIV Med. 2009;10(5):263–268. doi:10.1111/j.1468-1293.2008.00682.x
   PubMedGoogle Scholar
• Neto B, Andrade G, Lima R, Barros M, Junior J. Surgical lipodystrophy correction associated with the use of antiretroviral therapy: an analysis of procedures performed and impact on the patients. Brasileira De Cirurgia Plástica. 2001;30(2):250–257.
   Google Scholar
• Akinci B, Meral R, Oral EA. Update on therapeutic options in lipodystrophy. Curr Diab Rep. 2018;18(12):139. doi:10.1007/s11892-018-1100-7
   PubMed Web of Science ®Google Scholar
• Friedman JM, Mantzoros CS. 20 years of leptin: from the discovery of the leptin gene to leptin in our therapeutic armamentarium. Metabolism. 2015;64(1):1–4. doi:10.1016/j.metabol.2014.10.023
   PubMedGoogle Scholar
• Brown RJ, Oral EA, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine. 2018;60(3):479–489. doi:10.1007/s12020-018-1589-1
   PubMed Web of Science ®Google Scholar
• Püschel J, Miehle K, Müller K, et al. Beneficial effects of leptin substitution on impaired eating behavior in lipodystrophy are sustained beyond 150 weeks of treatment. Cytokine. 2019;113:400–404. doi:10.1016/j.cyto.2018.10.012
   PubMedGoogle Scholar
• McDuffie JR, Riggs PA, Calis KA, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab. 2004;89(9):4258–4263. doi:10.1210/jc.2003-031868
   PubMed Web of Science ®Google Scholar
• Kinzer AB, Shamburek RD, Lightbourne M, Muniyappa R, Brown RJ. Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy. J Endocr Soc. 2019;3(8):1503–1517. doi:10.1210/js.2019-00103
   PubMed Web of Science ®Google Scholar
• Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010;53(1):27. doi:10.1007/s00125-009-1502-9
   PubMed Web of Science ®Google Scholar
• Oral EA, Gorden P, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine. 2019;64(3):500–511
   PubMed Web of Science ®Google Scholar
• Sekizkardes H, Cochran E, Malandrino N, Garg A, Brown RJ. Efficacy of metreleptin treatment in familial partial lipodystrophy due to PPARG vs LMNA pathogenic variants. J Clin Endocrinol Metab. 2019;104(8):3068–3076. doi:10.1210/jc.2018-02787
   PubMedGoogle Scholar
• Ajluni N, Dar M, Xu J, Neidert AH, Oral EA. Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program. J Diabetes Metab. 2016;7(3).
   PubMed Web of Science ®Google Scholar
• Simha V, Subramanyam L, Szczepaniak L, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2012;97(3):785–792. doi:10.1210/jc.2011-2229
   PubMed Web of Science ®Google Scholar
• Oral EA, Ruiz E, Andewelt A, et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab. 2002;87(7):3110–3117. doi:10.1210/jcem.87.7.8591
   PubMed Web of Science ®Google Scholar
• Ebihara K, Kusakabe T, Hirata M, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2006;92(2):532–541. doi:10.1210/jc.2006-1546
   PubMedGoogle Scholar
• Musso C, Cochran E, Javor E, Young J, DePaoli AM, Gorden P. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism. 2005;54(2):255–263. doi:10.1016/j.metabol.2004.08.021
   PubMed Web of Science ®Google Scholar
• Lee HL, Waldman MA, Auh S, et al. Effects of metreleptin on proteinuria in patients with lipodystrophy. J Clin Endocrinol Metab. 2019;104(9):4169–4177. doi:10.1210/jc.2019-00200
   PubMedGoogle Scholar
• Vatier C, Kalbasi D, Vantyghem M-C, et al. Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes. Orphanet J Rare Dis. 2019;14(1):177. doi:10.1186/s13023-019-1141-2
   PubMedGoogle Scholar
• Chan JL, Koda J, Heilig JS, et al. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Clin Endocrinol (Oxf). 2016;85(1):137–149. doi:10.1111/cen.12980
   PubMedGoogle Scholar
• Aslam A, Savage DB, Coulson IH. Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infiltration. Int J Dermatol. 2015;54(7):827–829. doi:10.1111/ijd.12185
   PubMedGoogle Scholar
• Semple RK, Chatterjee VKK, O’Rahilly S. PPARγ and human metabolic disease. J Clin Invest. 2006;116(3):581–589. doi:10.1172/JCI28003
   PubMedGoogle Scholar
• Barroso I, Gurnell M, Crowley VEF, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402(6764):880. doi:10.1038/47254
   PubMed Web of Science ®Google Scholar
• Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000;9(1):109–112. doi:10.1093/hmg/9.1.109
   PubMed Web of Science ®Google Scholar
• Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. Nature. 2003;423(6937):293. doi:10.1038/nature01629
   PubMed Web of Science ®Google Scholar
• De Sandre-giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science. 2003;300(5628):2055. doi:10.1126/science.1084125
   PubMed Web of Science ®Google Scholar
• Novelli G, Muchir A, Sangiuolo F, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet. 2002;71(2):426–431. doi:10.1086/341908
   PubMed Web of Science ®Google Scholar
• Shastry S, Simha V, Godbole K, et al. A novel syndrome of mandibular hypoplasia, deafness, and progeroid features associated with lipodystrophy, undescended testes, and male hypogonadism. J Clin Endocrinol Metab. 2010;95(10):E192–E197. doi:10.1210/jc.2010-0419
   PubMed Web of Science ®Google Scholar
• Grahn THM, Zhang Y, Lee M-J, et al. FSP27 and PLIN1 interaction promotes the formation of large lipid droplets in human adipocytes. Biochem Biophys Res Commun. 2013;432(2):296–301. doi:10.1016/j.bbrc.2013.01.113
   PubMed Web of Science ®Google Scholar
• Kozusko K, Tsang VHM, Bottomley W, et al. Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. Diabetes. 2015;64(1):299–310. doi:10.2337/db14-0104
   PubMed Web of Science ®Google Scholar
• Gandotra S, Le Dour C, Bottomley W, et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med. 2011;364(8):740–748. doi:10.1056/NEJMoa1007487
   PubMed Web of Science ®Google Scholar
• Farhan SMK, Robinson JF, McIntyre AD, et al. A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy. Can J Cardiol. 2014;30(12):1649–1654. doi:10.1016/j.cjca.2014.09.007
   PubMed Web of Science ®Google Scholar
• Cavalcante MPV, Brunelli JB, Miranda CC, et al. CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature—a rare case with a novel mutation. Eur J Pediatr. 2016;175(5):735–740. doi:10.1007/s00431-015-2668-4
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Xing C, DeMartino GN, et al. PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet. 2010;87(6):866–872. doi:10.1016/j.ajhg.2010.10.031
   PubMed Web of Science ®Google Scholar
• Donadille B, D’Anella P, Auclair M, et al. Partial lipodystrophy with severe insulin resistance and adult progeria Werner syndrome. Orphanet J Rare Dis. 2013;8(1):106. doi:10.1186/1750-1172-8-106
   PubMedGoogle Scholar